{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:11:23Z","timestamp":1779253883583,"version":"3.51.4"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Precision therapy for non-small cell lung cancer (NSCLC) has expanded to include rare driver genes. RET fusion is a rare target in lung cancer, and data on targeted therapy combined with local consolidation surgery in advanced patients with oligometastatic status are limited. This article reports a case of successful surgical resection following initial systemic treatment with selpercatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 68-year-old never-smoking male was diagnosed with adenocarcinoma of the right upper lobe (cT3N3M1, stage IVA) with ipsilateral pulmonary metastasis and cervical and axillary lymph node metastases, consistent with oligometastatic features. A CCDC6-RET fusion was identified via next-generation sequencing. The patient received selpercatinib for three months as initial systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Post-treatment imaging assessment indicated a partial response. The patient subsequently underwent successful thoracoscopic anterior segmentectomy of the right upper lobe with lymph node dissection. Postoperative pathology confirmed 15% residual viable tumor cells, which did not achieve major pathological response (MPR). Due to marked shrinkage and scar-like changes in the originally enlarged lymph nodes after targeted therapy, limited lymph node dissection was performed intraoperatively, and all submitted lymph nodes were negative. The postoperative pathological stage was ypT1aN0M0. Adjuvant selpercatinib was continued postoperatively, with no signs of recurrence during 7 months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that for selected patients with advanced lung adenocarcinoma harboring a CCDC6-RET fusion and oligometastatic disease, initial systemic therapy with selpercatinib followed by local consolidative surgery is a feasible multimodal strategy. This is not a routine recommendation for stage IV lung cancer but requires individualized decision-making after multidisciplinary discussion in specific oligometastatic cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1811218","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:45:51Z","timestamp":1779252351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapy combined with local consolidative surgery for oligometastatic stage IVA lung adenocarcinoma with CCDC6-RET fusion: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Faxian","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Fan","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Outpatient Department, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingrui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Quais","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aier","family":"Zhou","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangyu","family":"Liu","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.12.018","article-title":"RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion","volume":"18","author":"Aldea","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.059","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003276","article-title":"IPDMA - RADICAL - NSCLC: individual participant data meta-analysis and systematic review of radical local therapy for oligometastatic NSCLC","volume":"12","author":"Tiwari","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00201","article-title":"Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34626","article-title":"Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis","volume":"10","author":"Peng","year":"2024","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00116-2","article-title":"RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature","volume":"8","author":"Baglivo","year":"2020","journal-title":"Oncol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061630","article-title":"Non-small-cell lung cancer patients with coexistence of high PD-L1 expression and RET fusion-which path should we follow? Case reports and literature review","volume":"11","author":"Knetki-Wr\u00f3blewska","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811218\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:46:11Z","timestamp":1779252371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811218\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":12,"alternative-id":["10.3389\/fonc.2026.1811218"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1811218","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1811218"}}